DE60315296D1 - Zell-selektives Abgabe System - Google Patents
Zell-selektives Abgabe SystemInfo
- Publication number
- DE60315296D1 DE60315296D1 DE60315296T DE60315296T DE60315296D1 DE 60315296 D1 DE60315296 D1 DE 60315296D1 DE 60315296 T DE60315296 T DE 60315296T DE 60315296 T DE60315296 T DE 60315296T DE 60315296 D1 DE60315296 D1 DE 60315296D1
- Authority
- DE
- Germany
- Prior art keywords
- cpp
- cell
- present
- relates
- delivery system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K51/0448—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil tropane or nortropane groups, e.g. cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Plant Pathology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201863A SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cell penetrating peptides |
SE0201863 | 2002-06-18 | ||
US39178802P | 2002-06-25 | 2002-06-25 | |
US391788P | 2002-06-25 | ||
PCT/IB2003/003163 WO2003106491A2 (en) | 2002-06-18 | 2003-06-18 | Cell penetrating peptides |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60315296D1 true DE60315296D1 (de) | 2007-09-13 |
DE60315296T2 DE60315296T2 (de) | 2008-04-17 |
Family
ID=29738564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60315296T Expired - Lifetime DE60315296T2 (de) | 2002-06-18 | 2003-06-18 | Zell-selektives Abgabe System |
Country Status (9)
Country | Link |
---|---|
US (1) | US20080234183A1 (de) |
EP (1) | EP1516184B1 (de) |
JP (1) | JP4503435B2 (de) |
AT (1) | ATE368853T1 (de) |
AU (1) | AU2003253125A1 (de) |
DE (1) | DE60315296T2 (de) |
HK (1) | HK1078130A1 (de) |
SE (1) | SE0201863D0 (de) |
WO (1) | WO2003106491A2 (de) |
Families Citing this family (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
US8003595B2 (en) | 2000-03-01 | 2011-08-23 | Cellectis | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
EP2348047A1 (de) * | 2000-04-21 | 2011-07-27 | New England Medical Center | G-Protein gekoppelte Rezeptor (GPCR)- agonisten und -antagonisten sowie Verfahren zur GPCR-Aktivierung/-Inhibierung |
US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
GB0313132D0 (en) * | 2003-06-06 | 2003-07-09 | Ich Productions Ltd | Peptide ligands |
EP1512696A1 (de) * | 2003-08-14 | 2005-03-09 | Diatos | Aminsäuresequenz, die den Transfer von Substanzen von Interesse in das Innere von Zellen und/oder Zellkernen erleichtern |
ES2330115T3 (es) * | 2003-08-14 | 2009-12-04 | Cellectis | Composicion antibacteriana, mas particilarmente contra las bacterias gram-negativas, que comprende un peptido y un agente antibacteriano ventajosamente hidrofobo. |
AU2004287884C1 (en) | 2003-11-05 | 2012-11-29 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
US20060040882A1 (en) | 2004-05-04 | 2006-02-23 | Lishan Chen | Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells |
MXPA06012605A (es) * | 2004-05-04 | 2006-12-15 | Nastech Pharm Co | Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas. |
WO2006049442A1 (en) * | 2004-11-03 | 2006-05-11 | Forhumantech. Co., Ltd. | Pharmaceutical compositions for transdermal delivery |
EP1814911A2 (de) * | 2004-11-04 | 2007-08-08 | New England Medical Center Hospitals, Inc. | G-protein-gekoppelte rezeptor-agonisten und antagonisten sowie verwendungsverfahren |
FR2877946B1 (fr) | 2004-11-12 | 2011-02-11 | Commissariat Energie Atomique | Peptides derives de la maurocalcine utilisables comme vecteurs pour l'adressage intracellulaire de molecules d'interet |
US7741275B2 (en) | 2004-12-22 | 2010-06-22 | Lipopeptide Ab | Agents and use thereof |
ES2399267T3 (es) | 2005-01-18 | 2013-03-27 | The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations | Suministro selectivo de moléculas al interior de las células o marcación de células en zonas enfermas de tejidos usando un péptido transmembrana sensible a su entorno |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
CN101351554B (zh) | 2005-10-04 | 2016-05-18 | 索利金尼克斯公司 | 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽 |
WO2007105565A1 (ja) * | 2006-03-13 | 2007-09-20 | Keio University | インフルエンザ感染阻害ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤 |
US8642559B2 (en) * | 2006-10-13 | 2014-02-04 | University Of Southern California | C-terminal domain truncation of mGluR1α by calpain and uses thereof |
PT2341142E (pt) | 2006-12-28 | 2015-02-13 | Int Inst Cancer Immunology Inc | Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo |
CA2676797C (en) * | 2007-01-29 | 2014-04-22 | Dae Woong Jo | Novel macromolecule transduction domains and methods for identification and uses thereof |
CA2939778C (en) | 2007-01-31 | 2019-01-29 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
DE102007008596B4 (de) * | 2007-02-15 | 2010-09-02 | Friedrich-Schiller-Universität Jena | Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung |
EP3159352B1 (de) | 2007-03-28 | 2023-08-02 | President and Fellows of Harvard College | Geheftete polypeptide |
US9078927B2 (en) * | 2007-07-06 | 2015-07-14 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
AU2008295509A1 (en) | 2007-08-29 | 2009-03-12 | Tufts University | Methods of making and using a cell penetrating peptide for enhanced delivery of nucleic acids, proteins, drugs, and adenovirus to tissues and cells, and compositions and kits |
WO2009041902A1 (en) * | 2007-09-25 | 2009-04-02 | Loefgren Kajsa | Prion protein derived cell penetrating peptides and their uses |
TW200932260A (en) * | 2007-11-28 | 2009-08-01 | Oncotherapy Science Inc | STAT3 epitope peptides |
EP2242503A4 (de) | 2008-02-08 | 2012-04-25 | Aileron Therapeutics Inc | Therapeutische peptidomimetische macrocyclen |
DE102009043743B4 (de) | 2009-03-13 | 2016-10-13 | Friedrich-Schiller-Universität Jena | Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung |
EP2090584A1 (de) | 2008-02-13 | 2009-08-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Identifikation eines neuartigen Zystein-reichen Peptids zur Zellenpenetration |
CA2713872A1 (en) * | 2008-02-21 | 2009-08-27 | Burnham Institute For Medical Research | Methods and compositions related to peptides and proteins with c-terminal elements |
GB0804496D0 (en) | 2008-03-11 | 2008-04-16 | Theryte Ltd | Treating cancer |
WO2009120993A2 (en) * | 2008-03-28 | 2009-10-01 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof |
WO2009137689A2 (en) * | 2008-05-07 | 2009-11-12 | Surmodics, Inc. | Delivery of nucleic acid complexes from particles |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
US20110250685A1 (en) * | 2008-06-03 | 2011-10-13 | Nash Huw M | Compositions and methods for enhancing cellular transport of biomolecules |
US8575305B2 (en) | 2008-06-04 | 2013-11-05 | Medical Research Council | Cell penetrating peptides |
EP3168231A1 (de) | 2008-06-12 | 2017-05-17 | Centre for Addiction and Mental Health | Zusammensetzungen und verfahren zur modulierung der d1-d2-dopaminrezeptorinteraktion und -funktion |
US20110218334A1 (en) * | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
WO2010011313A2 (en) | 2008-07-23 | 2010-01-28 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
CA2737921C (en) | 2008-09-22 | 2019-01-15 | Aileron Therapeutics, Inc. | Methods for preparing purified alpha-helical peptidomimetic macrocycle compositions with low metal ppm levels |
US20140248296A1 (en) * | 2008-10-16 | 2014-09-04 | Kathleen Cogan Farinas | Sustained drug delivery system |
US20110294738A1 (en) * | 2008-11-04 | 2011-12-01 | Yong Ren | Pthr1 receptor compounds |
WO2010053547A2 (en) * | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Cxcr5 receptor compounds |
WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
EP2641911A3 (de) * | 2008-12-23 | 2014-01-01 | Vivoscript, Inc. | Zusammensetzungen und Verfahren zur Neuprogrammierung von Zellen ohne genetische Modifikation |
CA2744088A1 (en) | 2009-01-14 | 2010-07-22 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
US8658762B2 (en) | 2009-04-09 | 2014-02-25 | Centre For Addiction And Mental Health | Polypeptides that inhibit dopamine D2 receptor-DISC1 interaction and methods of use thereof |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
GB0910620D0 (en) | 2009-06-19 | 2009-08-05 | Immunovia Ab | Agents and uses thereof |
CA2766634A1 (en) | 2009-06-22 | 2011-01-13 | Burnham Institute For Medical Research | Methods and compositions using peptides and proteins with c-terminal elements |
BR112012000867A2 (pt) | 2009-07-13 | 2019-09-24 | Harvard College | "polipeptídeos bifuncional costurado e uso do mesmo" |
WO2011038002A1 (en) * | 2009-09-22 | 2011-03-31 | Yale University | Immunogenic epitopes as targets for universal cancer vaccines |
US20130072439A1 (en) | 2009-09-22 | 2013-03-21 | Huw M. Nash | Peptidomimetic macrocycles |
AU2010306940A1 (en) | 2009-10-12 | 2012-06-07 | Smith, Larry | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
WO2011072292A2 (en) * | 2009-12-11 | 2011-06-16 | Dicerna Pharmaceuticals, Inc. | Phase changing formulations of rna and rna derivatives |
US20110159098A1 (en) * | 2009-12-30 | 2011-06-30 | Surmodics, Inc. | Stabilization and delivery of nucleic acid complexes |
CA2797093C (en) | 2010-04-26 | 2019-10-29 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
US8993723B2 (en) | 2010-04-28 | 2015-03-31 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases |
AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
WO2011139907A2 (en) | 2010-04-29 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases |
EP2566495B1 (de) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-alpha-trna-synthetasen |
AU2011248355B2 (en) | 2010-05-03 | 2017-01-19 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Arginyl-tRNA synthetases |
WO2011140135A2 (en) | 2010-05-03 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases |
EP2566499B1 (de) | 2010-05-04 | 2017-01-25 | aTyr Pharma, Inc. | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex |
AU2011252990B2 (en) | 2010-05-14 | 2017-04-20 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases |
JP6046607B2 (ja) | 2010-05-27 | 2016-12-21 | エータイアー ファーマ, インコーポレイテッド | グルタミニルtRNA合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見 |
CN103118694B (zh) | 2010-06-01 | 2016-08-03 | Atyr医药公司 | 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现 |
US9540680B2 (en) * | 2010-06-07 | 2017-01-10 | The Trustees Of The University Of Pennsylvania | Transcriptome in vivo analysis |
WO2011157713A2 (en) | 2010-06-14 | 2011-12-22 | F. Hoffmann-La Roche Ag | Cell-penetrating peptides and uses therof |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
JP2013534525A (ja) * | 2010-06-23 | 2013-09-05 | ヴィヴォスクリプト,インコーポレイテッド | 心臓疾患の治療のために遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法 |
CA2804416C (en) | 2010-07-12 | 2020-04-28 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
EP2611791A4 (de) | 2010-08-12 | 2014-02-12 | Univ New York | Oligooxopiperazine sowie verfahren zu ihrer herstellung und verwendung |
WO2012021876A2 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
JP5753903B2 (ja) * | 2010-08-24 | 2015-07-22 | ロシュ グリクアート アーゲー | 活性化可能な二重特異性抗体 |
CA2807278A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann - La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
CA2808539C (en) | 2010-08-25 | 2021-05-25 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases |
WO2012040459A2 (en) | 2010-09-22 | 2012-03-29 | President And Fellows Of Harvard College | Beta-catenin targeting peptides and uses thereof |
CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
US9518105B2 (en) * | 2010-12-08 | 2016-12-13 | The Research Foundation For The State University Of New York | Polypeptides derived from calcitonin receptors and methods of use |
US20140056811A1 (en) | 2010-12-27 | 2014-02-27 | Compugen Ltd. | New cell-penetrating peptides and uses thereof |
US8901092B2 (en) | 2010-12-29 | 2014-12-02 | Surmodics, Inc. | Functionalized polysaccharides for active agent delivery |
WO2012116927A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
WO2012118778A1 (en) | 2011-02-28 | 2012-09-07 | Sanford-Burnham Medical Research Institute | Truncated car peptides and methods and compositions using truncated car peptides |
AR085404A1 (es) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas de union a antigeno |
WO2012139137A2 (en) | 2011-04-08 | 2012-10-11 | Tufts Medical Center, Inc. | Pepducin design and use |
CA2834577A1 (en) * | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
EP2715291A4 (de) | 2011-05-31 | 2015-10-21 | Airware Inc | Rekalibrierung von ab-ndir-gassensoren |
US9487562B2 (en) | 2011-06-17 | 2016-11-08 | President And Fellows Of Harvard College | Stabilized polypeptides as regulators of RAB GTPase function |
EP2537858A1 (de) | 2011-06-20 | 2012-12-26 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Kleine effiziente zelleindringende Peptide aus dem Skorpiongift Maurocalcin |
US10179801B2 (en) | 2011-08-26 | 2019-01-15 | Sanford-Burnham Medical Research Institute | Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides |
US9302014B2 (en) | 2011-08-30 | 2016-04-05 | Medical Research Council | Cell-penetrating peptides having a central hydrophobic domain |
US9624284B2 (en) * | 2011-09-13 | 2017-04-18 | Immunotope, Inc. | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer |
WO2013059525A1 (en) | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
CN104487450B (zh) | 2011-11-24 | 2018-09-21 | 苏州宝时得电动工具有限公司 | 多肽序列设计及其在多肽介导的siRNA传递中的应用 |
CN102532565B (zh) * | 2011-12-19 | 2013-08-28 | 上海交通大学 | 可降解亚胺类聚阳离子及其合成方法、纳米颗粒 |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
CN104144695A (zh) | 2012-02-15 | 2014-11-12 | 爱勒让治疗公司 | 三唑交联的和硫醚交联的拟肽大环化合物 |
CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
WO2013123511A1 (en) | 2012-02-16 | 2013-08-22 | New York University | Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics |
EP2864348A2 (de) | 2012-06-26 | 2015-04-29 | F. Hoffmann-La Roche AG | Zellpenetrierende peptide und verfahren zur identifikation zellpenetrierende peptide |
AU2013296218B2 (en) | 2012-08-03 | 2019-07-18 | Cedars-Sinai Medical Center | Isolating traffic-enhancing mutants of drug delivery protein |
EP2708235A1 (de) | 2012-09-17 | 2014-03-19 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Peptidantagonisten des Vasopressin-2-Rezeptors |
EP3872067A1 (de) | 2012-09-26 | 2021-09-01 | President And Fellows Of Harvard College | Prolinderivate |
SG11201503052RA (en) | 2012-11-01 | 2015-05-28 | Aileron Therapeutics Inc | Disubstituted amino acids and methods of preparation and use thereof |
AU2013347797A1 (en) * | 2012-11-25 | 2015-07-02 | The Regents Of The University Of California | Peptides that stimulate subcutaneous adipogenesis |
ITMI20122263A1 (it) * | 2012-12-28 | 2014-06-29 | Azienda Ospedaliero Universitaria Di Parma | Nuovi peptidi cationici ciclici ad attività antimicrobica |
CA3085079A1 (en) | 2013-03-13 | 2014-10-02 | President And Fellows Of Harvard College | Stapled and stitched polypeptides and uses thereof |
EP2784094A1 (de) | 2013-03-28 | 2014-10-01 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Neue uranchelatisierende, vom EF-Hand-Calciumsbindungsmotiv abgeleitete Peptide zur Uran-Biodetektion und -Biodekontamination |
EP2981555B1 (de) | 2013-03-28 | 2020-04-15 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Neue uranchelatisierende, vom ef-hand-calciumsbindungsmotiv abgeleitete peptide zur uran-biodetektion und -biodekontamination |
CN105492460A (zh) | 2013-06-14 | 2016-04-13 | 哈佛大学的校长及成员们 | 稳定化多肽胰岛素受体调控剂 |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
US20160146786A1 (en) * | 2013-06-26 | 2016-05-26 | Phylogica Limited | Method of monitoring cellular trafficking of peptides |
KR20160023669A (ko) | 2013-06-26 | 2016-03-03 | 자이겐 인플라메이션 리미티드 | 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도 |
EP2842566A1 (de) | 2013-09-03 | 2015-03-04 | Centre National De La Recherche Scientifique | Verwendung von Arpin als neuer Hemmer des ARP2/3-Komplexes zur Diagnose und Behandlung von Krankheiten |
JP6422956B2 (ja) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性ドメイン交換共通可変軽鎖抗体 |
JP6493216B2 (ja) * | 2013-11-05 | 2019-04-03 | 味の素株式会社 | ペプチドヒドラジド、ペプチドアミド及びペプチドチオエステルの製造方法 |
JP6865584B2 (ja) * | 2013-12-23 | 2021-04-28 | コヴァラブ | 化合物の共有結合性コンジュゲーションのためのmTG基質 |
WO2015105957A1 (en) * | 2014-01-08 | 2015-07-16 | Shriners Hospitals For Children | Pten antagonist peptides and methods of using the same |
WO2015108955A2 (en) * | 2014-01-15 | 2015-07-23 | The Board Of Regents Of The University Of Texas System | Targeting of pelp1 in cancer therapy |
EP3791889B1 (de) | 2014-01-17 | 2024-02-21 | Cedars-Sinai Medical Center | Auf den c-met rezeptor abzielende konstrukte und verwendungen davon |
EP2905031A1 (de) | 2014-02-10 | 2015-08-12 | B Cell Design | Neues, nicht-HIV-Impfstoff-Antigen aus der vaginalen Mikrobiota zur Induzierung einer mukosalen, neutralisierenden, schützenden Antikörperreaktion gegen eine HIV-Infektion |
MX2016013025A (es) | 2014-04-04 | 2017-04-27 | Cedars Sinai Medical Center | Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3. |
CA2949535C (en) | 2014-05-21 | 2023-09-12 | President And Fellows Of Harvard College | Ras inhibitory peptides and uses thereof |
US10844102B2 (en) | 2014-05-28 | 2020-11-24 | The Regents Of The University Of California | Peptides, compositions, and methods for stimulating subcutaneous adipogenesis |
CA2961258A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
MX2017003819A (es) | 2014-09-24 | 2017-06-15 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y formulaciones de los mismos. |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
CA2979847A1 (en) | 2015-03-20 | 2016-09-29 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
PL3388075T3 (pl) | 2015-03-27 | 2023-12-11 | Immatics Biotechnologies Gmbh | Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem różnych nowotworów |
US9795624B2 (en) | 2015-05-04 | 2017-10-24 | Research Foundation Of The City University Of New York | Cationic polymers as co-drugs for chemotherapeutic agents |
US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
WO2017083618A1 (en) | 2015-11-13 | 2017-05-18 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
WO2017087505A1 (en) * | 2015-11-17 | 2017-05-26 | The Regents Of The University Of Michigan | Macromolecular structures and uses thereof |
EP4039698A1 (de) | 2016-03-15 | 2022-08-10 | IDP Discovery Pharma, S.L. | Peptide mit antikrebsaktivität |
GB201607521D0 (en) * | 2016-04-29 | 2016-06-15 | Oncolmmunity As | Method |
EP3484482A4 (de) * | 2016-07-15 | 2020-07-29 | The Board of Regents of the University of Oklahoma | Anti-arid3a-behandlungen für entzündliche erkrankungen |
GB201618432D0 (en) * | 2016-11-01 | 2016-12-14 | Matn Scient Ltd | Detection and treatment of demyelinating diseases |
TWI781963B (zh) | 2016-11-09 | 2022-11-01 | 俄亥俄州立創新基金會 | 含二硫化物細胞穿透肽及其製造與使用方法 |
US11352394B2 (en) | 2016-11-22 | 2022-06-07 | Ohio State Innovation Foundation | Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof |
IL293710B2 (en) | 2016-12-07 | 2024-10-01 | Molecular Templates Inc | Shiga toxin A subunit activator polypeptides, Shiga toxin activator scaffolds and cell-targeting molecules for site-specific conjugation |
EP3360891B1 (de) | 2017-02-14 | 2022-03-30 | Karlsruher Institut für Technologie | Zellenpenetrierende peptide menschlichen ursprungs |
EP3628047A1 (de) | 2017-05-02 | 2020-04-01 | Sanford Burnham Prebys Medical Discovery Institute | Tumorassoziiertes monozyten-/makrophagenbindendes peptid und verfahren zur verwendung davon |
KR102095284B1 (ko) * | 2017-05-11 | 2020-04-01 | (주)케어젠 | 메토트렉세이트와 펩타이드의 결합체 |
EP3654941A1 (de) | 2017-07-17 | 2020-05-27 | Keith Roizman | Topische verabreichung von therapeutischen mitteln mit zellpenetrierenden peptiden zur verwendung zur behandlung von altersbedingter makuladegeneration und anderen augenerkrankungen |
US20200223894A1 (en) * | 2017-09-19 | 2020-07-16 | Auckland Uniservices Limited | Peptides for the treatment of conditions associated with adiponectin dysfunction |
AU2018378201A1 (en) * | 2017-12-04 | 2020-05-21 | Heat Biologics, Inc. | Production of cell-based vaccines |
US20210363192A1 (en) * | 2018-04-27 | 2021-11-25 | Spark Therapeutics, Inc. | Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same |
WO2019217682A1 (en) | 2018-05-09 | 2019-11-14 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
KR102167755B1 (ko) | 2018-05-23 | 2020-10-19 | 주식회사 큐어바이오 | 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도 |
WO2020010103A1 (en) * | 2018-07-02 | 2020-01-09 | Ohio State Innovation Foundation | Polypeptide conjugates for intracellular delivery of nucleic acids |
KR20210064254A (ko) * | 2018-09-26 | 2021-06-02 | 가부시키가이샤 가네카 | 세포막 투과성 펩티드 |
JP2022528298A (ja) * | 2018-12-07 | 2022-06-10 | オックスフォード ユニバーシティ イノベーション リミテッド | リンカー |
CN118079011A (zh) | 2019-02-01 | 2024-05-28 | 利兰斯坦福初级大学董事会 | 用于将核酸递送至肺部的分解性细胞穿透复合物 |
US20220119450A1 (en) * | 2019-02-04 | 2022-04-21 | University Of Tartu | Bi-specific extracellular matrix binding peptides and methods of use thereof |
US20220259273A1 (en) * | 2019-03-05 | 2022-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating protein aggregation-associated diseases |
KR20220034182A (ko) | 2019-07-11 | 2022-03-17 | 시아먼 유니버시티 | 분자의 세포내 전달용 복합체 |
US20210038729A1 (en) * | 2019-07-22 | 2021-02-11 | Oneskin, Inc. | Polypeptides having anti-senescent effects and uses thereof |
AR119529A1 (es) * | 2019-08-02 | 2021-12-22 | Idp Discovery Pharma S L | Péptidos reguladores de melanocitos |
KR20220121867A (ko) | 2019-12-31 | 2022-09-01 | 시아먼 유니버시티 | 분자의 세포 내 전달을 위한 다량체화 전달 시스템 |
EP3906935A1 (de) | 2020-05-06 | 2021-11-10 | Sorbonne Universite | Peptide zur vorbeugung oder behandlung viraler infektionen |
CN113943778A (zh) * | 2020-07-17 | 2022-01-18 | 通用电气医疗集团股份有限公司 | 用于核酸检测的分子探针及其制备方法和用途 |
WO2022157548A1 (en) | 2021-01-24 | 2022-07-28 | Forrest Michael David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
US20240182526A1 (en) * | 2021-03-31 | 2024-06-06 | University Of Southern California | Compositions and methods for modulting inflammatory and degenerative disorder |
JP2024513087A (ja) | 2021-04-07 | 2024-03-21 | アストラゼネカ・アクチエボラーグ | 部位特異的改変のための組成物及び方法 |
CN115385987B (zh) * | 2021-05-19 | 2024-08-02 | 中山大学 | 一种抗鱼类神经坏死病毒的穿膜肽及其应用 |
KR102504190B1 (ko) * | 2021-06-03 | 2023-02-28 | 주식회사 레메디 | 화물분자 수송 도메인 rmmr1, 이의 변이체, 이를 포함하는 재조합 화물분자 및 이를 이용한 화물분자 수송 방법 |
CN114349846B (zh) * | 2022-01-07 | 2023-12-15 | 天津市泌尿外科研究所 | 一种人精子膜蛋白or1d2特异性多肽与抗体的制备方法 |
WO2023181070A1 (en) * | 2022-03-23 | 2023-09-28 | Council Of Scientific & Industrial Research | PEPTIDE TO TREAT α-SYNUCLEIN AMYLOID BASED DISORDERS |
CN116444678B (zh) * | 2022-10-18 | 2024-02-02 | 百葵锐(深圳)生物科技有限公司 | 一种具有真菌抗菌抑菌性能的新型多肽 |
WO2024119101A1 (en) | 2022-12-01 | 2024-06-06 | Yale University | Stimuli-responsive traceless engineering platform for intracellular payload delivery |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE251913T1 (de) * | 1997-05-21 | 2003-11-15 | Univ Leland Stanford Junior | Zusammensetzung und verfahren zur verzögerung des transports durch biologische membranen |
JP4465109B2 (ja) * | 1997-12-17 | 2010-05-19 | エンゾン ファーマシューティカルズ,インコーポレーテッド | アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ |
CA2354044A1 (en) * | 1998-12-10 | 2000-06-15 | Washington University | Protein transduction system and methods of use thereof |
WO2001097830A1 (en) * | 2000-06-22 | 2001-12-27 | Mount Sinai School Of Medicine | Modification of mdm2 activity |
FR2810985B1 (fr) * | 2000-07-03 | 2004-12-24 | Synt Em | Peptides lineaires amphipathiques et les compositions les contenant |
NZ524386A (en) * | 2000-08-25 | 2005-10-28 | Aventis Pharma Inc | Membrane penetrating peptides and uses thereof |
EP1581615B1 (de) * | 2000-09-05 | 2010-04-28 | Biosight Ltd | Peptid-konjugierte antikrebs-prodrugs |
FR2818981A1 (fr) * | 2001-01-03 | 2002-07-05 | Synt Em | Peptides amphipathiques et leur utilisation pour le transfert de substances d'interet dans les cellules |
AU2002240201A1 (en) * | 2001-02-02 | 2002-08-19 | Yale University | Peptides for facilitating composite receptor expression and translocation of macromolecules |
WO2003064453A2 (de) * | 2002-01-27 | 2003-08-07 | Viromics Gmbh | Trojanische inhibitoren, verfahren zu ihrer herstellung und ihre verwendung |
-
2002
- 2002-06-18 SE SE0201863A patent/SE0201863D0/ unknown
-
2003
- 2003-06-18 AT AT03760107T patent/ATE368853T1/de not_active IP Right Cessation
- 2003-06-18 WO PCT/IB2003/003163 patent/WO2003106491A2/en active Search and Examination
- 2003-06-18 DE DE60315296T patent/DE60315296T2/de not_active Expired - Lifetime
- 2003-06-18 US US10/517,079 patent/US20080234183A1/en not_active Abandoned
- 2003-06-18 AU AU2003253125A patent/AU2003253125A1/en not_active Abandoned
- 2003-06-18 EP EP03760107A patent/EP1516184B1/de not_active Expired - Lifetime
- 2003-06-18 JP JP2004513322A patent/JP4503435B2/ja not_active Expired - Fee Related
-
2005
- 2005-09-23 HK HK05108432.4A patent/HK1078130A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1078130A1 (en) | 2006-03-03 |
US20080234183A1 (en) | 2008-09-25 |
AU2003253125A8 (en) | 2003-12-31 |
DE60315296T2 (de) | 2008-04-17 |
JP4503435B2 (ja) | 2010-07-14 |
AU2003253125A1 (en) | 2003-12-31 |
WO2003106491A2 (en) | 2003-12-24 |
WO2003106491A3 (en) | 2004-12-23 |
EP1516184A2 (de) | 2005-03-23 |
SE0201863D0 (en) | 2002-06-18 |
ATE368853T1 (de) | 2007-08-15 |
EP1516184B1 (de) | 2007-08-01 |
JP2006514602A (ja) | 2006-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60315296D1 (de) | Zell-selektives Abgabe System | |
UA101309C2 (ru) | Антагонисты активина-actrii и их применение для повышения уровня эритроцитов | |
IL189452A0 (en) | Therapy with cd4 binding peptides and radiation | |
GEP20125594B (en) | Sclerostin binding agents | |
HUP0300246A2 (en) | Delivery system | |
IL178515A0 (en) | Oligopeptides for reducing elevated blood urea concentration | |
DE60236206D1 (de) | Spiroazacyclische verbindungen als monoaminrezeptormodulatoren | |
HK1089190A1 (en) | Rasgap derived peptide for selectively killing cancer cells | |
DE69938935D1 (de) | Zyklische conotoxin-peptide | |
WO2009047513A3 (en) | Antagonists of kisspeptin and uses thereof | |
CY1109803T1 (el) | Φαρμακευτικες συνθεσεις που βασιζονται σε ανταγωνιστες νκ2 για παιδιατρικη χρηση | |
DE59809283D1 (de) | Inhibitoren für den urokinaserezeptor | |
EP1801232A4 (de) | Verfahren zum screening eines transmembranenzymhemmstoffs | |
TW200508249A (en) | Antibodies for the cancer specific antigen | |
EA200700990A1 (ru) | Новые пептиды, которые связывают рецептор эритропоэтина | |
ATE360644T1 (de) | Vegf-peptide und deren verwendung | |
TW200517125A (en) | Pharmaceutical composition for treatment of solid cancers | |
WO2010133806A3 (fr) | Peptides marques et leur utilisation pour le dosage d'irap circulant | |
WO2006113429A3 (en) | Viral inhibitors | |
SI1668027T1 (sl) | Ciklični peptidi delujoči kot antagonisti urotenzina ii | |
DE60327467D1 (de) | Mss4 als antifungisches zielmolekül | |
SE0401166D0 (sv) | Method for protein protection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8381 | Inventor (new situation) |
Inventor name: HAELLBRINK, MATTIAS, S-113 28 STOCKHOLM, SE Inventor name: POOGA, MARGUS, E-51010 TARTU, EE Inventor name: METSIS, MADIS TALLIN UNIVE, 12618 TALLINN, EE Inventor name: KOGERMAN, PRIIT, E-79601 TABASALU, EE Inventor name: VALKNA, ANDREAS, VIIMSI, EE Inventor name: MEIKAS, ANNE, SAKU ESTONIA, EE Inventor name: LINDGREN, MARIA, S-113 28 STOCKHOLM, SE Inventor name: GRAESLUND, ASTRID, S-191 44 SOLLENTUNA, SE Inventor name: ERIKSSON, GOERAN, S-116 43 STOCKHOLM, SE Inventor name: OESTENSSON, CLAES GOERAN, S-171 64 SOLNA, SE Inventor name: BUDIHNA, METKA, 1210 LJUBLJANA-SENTVID, SI Inventor name: ZORKO, MATJAZ, SKOFLJICA, SI Inventor name: ELMQUIST, ANNA, S-761 71 NORRTAELJE, SE Inventor name: SOOMETS, URSEL, TARTU, EE Inventor name: LUNDBERG, PONTUS, S-169 72 SOLNA, SE Inventor name: JAERVER, PETER, S-116 67 STOCKHOLM, SE Inventor name: SAAR, KUELLIKI, S-113 53 STOCKHOLM, SE Inventor name: EL-ANDALOUSSI, SAMIR, S-104 05 STOCKHOLM, SE Inventor name: KILK, KALLE, S-182 38 DANDERYD, SE Inventor name: LANGEL, UELO, S-124 32 BANDHAGEN, SE |
|
8364 | No opposition during term of opposition |